Loteprednol Etabonate Suspension 0.2% Administered QID Compared With Olopatadine Solution 0.1% Administered BID in the Treatment of Seasonal Allergic Conjunctivitis: A Multicenter, Randomized, Investigator-Masked, Parallel Group Study in Chinese Patients-Reference-Cited by-同舟云学术

Loteprednol Etabonate Suspension 0.2% Administered QID Compared With Olopatadine Solution 0.1% Administered BID in the Treatment of Seasonal Allergic Conjunctivitis: A Multicenter, Randomized, Investigator-Masked, Parallel Group Study in Chinese Patients

Published:2012-06 Issue:6 Volume:34 Page:1259-1272.e1
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Gong Lan,Sun Xinghuai,Qu Jia,Wang Lili,Zhang Mingzhi,Zhang Hong,Wang Linnong,Gu Yangshun,Elion-Mboussa Albert,Roy Lipika,Zhu Byron

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference32 articles.

1. Management of seasonal allergic conjunctivitis (SAC): current therapeutic strategies;Anderson;Clin Exp Allergy,2001

2. The epidemiology of ocular and nasal allergy in the United States, 1988–1994;Singh;J Allergy Clin Immunol,2010

3. Treating the ocular component of allergic rhinoconjunctivitis and related eye disorders;Bielory;MedGenMed,2007

4. Management of seasonal allergic conjunctivitis: guide to therapy;Bielory;Acta Ophtahlmol,2011

5. Developments in ocular allergy;Chambless;Curr Opin Allergy Clin Immunol,2004

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of alcaftadine with olopatadine for allergic conjunctivitis: A meta-analysis study;Revue Française d'Allergologie;2023-10

2. Comparison of olopatadine with ketotifen for allergic conjunctivitis: a meta-analysis study;Advances in Dermatology and Allergology;2023

3. “A COMPARATIVE STUDY OF EFFICACY AND SAFETY OF ALCAFTADINE 0.25% VERSUS OLOPATADINE HYDROCHLORIDE 0.2% IN ALLERGIC CONJUNCTIVITIS AT A TERTIARY CARE HOSPITAL”;INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH;2022-12-01

4. Executive summary: Japanese guidelines for allergic conjunctival diseases 2021;Allergology International;2022-10

5. Comparative analysis of safety and efficacy of Alcaftadine 0.25%, Olopatadine hydrochloride 0.2% and Bepotastine besilate 1.5% in allergic conjunctivitis;Indian Journal of Ophthalmology;2021